Clinical trials: Impulse Control Disorder
Delayed Sleep Phase
Delayed Sleep Timing in Teens Study
This study will (1) comprehensively characterize the substance use disorder (SUD) risk profile associated with adolescent Delayed Sleep Phase (DSP), and (2) probe whether SUD risk is diminished by altering sleep/circadian timing.
- Trial name
- NCT03806296
- Testing
- Increase morning bright light, Decrease evening blue light, Sleep scheduling
- Where
- United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Pathological Gambling
D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement
To determine if: 1. pathological gambling is similar to psychostimulant addiction as reflected by parallel roles for D1 and D2 receptors in gambling and stimulant reinforcement. 2.
- Trial name
- HFDEX (NCT02203786)
- Testing
- Haloperidol, Fluphenazine, Dexedrine
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Modified DECIDE Intervention, Treatment as Usual Care Group
The DECIDE Parent-Provider Intervention
The DECIDE Parent-Provider Intervention is designed to support parents caring for adolescents who are receiving treatment for Disruptive, Impulse-Control, and Conduct disorders.
- Trial name
- NCT04445155
- Testing
- Modified DECIDE Parent and Provider Intervention
- Where
- 5 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Indiana University
Pathological Gambling
Acamprosate in the Treatment of Pathological Gambling
The purpose of this study is to see whether acamprosate (Campral) will curb the desire to gamble in people with pathological gambling disorder.
- Trial name
- NCT00571103
- Testing
- acamprosate
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Iowa
Gambling
Drug Treatment for Pathologic Gambling Disorder
This study will establish the best dose of the drug naltrexone to treat patients with Pathological Gambling Disorder (PGD) and severe urge symptoms.
- Trial name
- NCT00053677
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University of Chicago